Genmab — November 2017
-
men Per Hansen har nu helt ret i, at det er frygtelig ringe rapportering fra GEN's side
-
Rasmus Botoft: "Vi skal længere "ned"... vi skal helt "ned" i sindet... nu er du bange!!... nu-men-sas... nu-men-sas!"
-
Ja, det må du sgu nok sige concillado - usikkerher er gift for aktier.
-
GEN har altid trukket regnskabet til meget sent
-
lidt underligt egentligt, da der ikke kan gå meget energi i at lave en opdateret opgørelse over omsætningen...
-
Johnson & Johnson's Janssen Biotech unit entered a licensing deal with Zymeworks potentially worth more than $1.4 billion to develop up to six bispecific antibodies directed against undisclosed therapeutic targets, Zymeworks announced Monday. Under the agreement, which includes an upfront payment from Janssen of $50 million, the drugmaker will obtain a royalty-bearing license to use Zymeworks' Azymetric and EFECT platforms
-
As part of the transaction, Zymeworks is eligible to receive up to $282 million in development and up to $1.12 billion in commercial milestone payments, and tiered royalties on potential sales. Janssen also has the option to develop two additional bispecific programmes subject to a future option payment.
-
-
Et spændende 2018 vi går i møde
-
Jans optimisme ser efterhånden noget vingeskudt ud ifht, hvordan virkeligheden udvikler sig
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind